血液感染检测市场－全球产业规模、份额、趋势、机会、预测：按产品、样本类型、技术、最终用户、地区和竞争对手划分，2021-2031年

全球血液感染检测市场预计将从 2025 年的 8.505 亿美元成长到 2031 年的 11.4041 亿美元，复合年增长率达到 5.01%。

此领域涵盖用于检测和识别血液样本中病原体（例如细菌和真菌）的诊断设备、耗材和软体。其成长主要受败血症发病率上升以及透过准确的病原学诊断控制抗生素抗药性的重要性所驱动。欧洲疾病预防控制中心在2024年报告称，欧盟第三代头孢菌素抗药性大肠桿菌血流感染的估计总发病率为每10万人11.03例，凸显了准确检测在製定治疗策略和促进患者康復方面发挥的关键作用，也强调了这一问题的紧迫性。

然而，自动化分子诊断系统的高成本和技术复杂性构成了市场推广的重大障碍。许多医疗机构，尤其是在开发中国家，面临预算限制，难以实施这些快速检测方案，导致他们仍然依赖传统的培养为基础的检测方法。这些经济障碍阻碍了及时做出治疗决策，限制了先进诊断技术的普及，并最终导致这些技术在最需要的地区无法应用。

市场驱动因素

抗生素抗药性的加剧是全球血液感染检测市场的主要驱动因素。随着病原体发展出对抗标准疗法的防御机制，医疗机构对能够同时识别致病菌并确定其抗生素敏感性谱的诊断工具的需求日益增长。抗药性菌株的出现使得使用先进的检测平台成为必要，以便进行精准的治疗性介入并预防死亡。例如，英国卫生与安全局于2024年11月发布的《英格兰抗生素处方和使用监测报告》指出，英格兰由抗生素抗药性引起的菌血症病例年增9.3%，2024年达到20484例。这凸显了对能够有效控制抗药性感染疾病的诊断方法的迫切需求。

同时，快速分子诊断技术的进步显着提高了病原体检测的速度和准确性。传统的培养方法需要数天才能得出结果，这可能导致败血症治疗的严重延误，而现代平台可在数小时内提供可操作的数据，从而优化临床工作流程。 T2 Biosystems公司于2024年3月在《临床微生物学杂誌》（Journal of Clinical Microbiology）上发表的一项研究表明，T2抗药性检测板的灵敏度高达94.7%，且仅需4.4小时即可得出结果，而标准血液培养则需要超过58小时。这项功能优势吸引了大量投资。根据《呼吸治疗》（Respiratory Therapy）杂誌报道，诊断设备製造商Cytovale于2024年获得了1亿美元的D轮资金筹措，旨在加速将快速脓毒症检测技术推广到医院系统。

市场挑战

自动化分子诊断平台的高昂成本和技术复杂性是全球血液感染检测市场扩张的主要障碍。高昂的实施成本以及对专业操作技能的要求，使得许多医疗机构，尤其是在财政状况严峻的地区，难以采用这些系统。这些经济和营运方面的障碍检查室依赖耗时更长的传统培养方法，导致关键治疗决策延误，并阻碍了现代检测技术的应用。

由于诊断解决方案的预算拨款极少，医疗机构的购买力受到限制，这进一步加剧了其财务负担。根据欧洲医疗技术协会（MedTech Europe）预测，至2024年，欧洲体外诊断支出仅占医疗总支出的0.6%。此类投资限制凸显了医疗机构在为部署高成本自动化平台资金筹措方面所面临的挑战。因此，持续的资金短缺直接阻碍了市场成长，因为全球大部分医疗机构仍然无法获得这些设备的先进功能。

市场趋势

人工智慧 (AI) 和机器学习演算法的整合正在从根本上改变临床工作流程，将重点从简单的病原体检测转移到预测性风险分层。与在感染确诊后才识别病原体的传统诊断方法不同，AI 模型分析宿主的免疫反应和生命征象波动，从而提前数小时预测脓毒症的发生，使临床医生能够在不可逆的器官损伤发生之前进行干预。为了支持这项创新，Prenosis 在 2024 年 4 月的新闻稿「Prenosis 的脓毒症新核准，该评分是一款用于脓毒症风险评估的 AI 工具」中宣布，其人工智慧工具已获得首个上市核准，该工具可评估 22 个独立参数。

策略性的产业重组和合作伙伴关係正在进一步加速市场变革，领先的诊断设备製造商致力于提供全面的端到端脓毒症管理解决方案。主要企业正在收购专注于特定领域的软体和技术公司，以弥合诊断硬体与合理使用抗菌药物管理之间的差距，将单一设备转变为整合的数据生态系统，从而增强全院的决策能力。例如，生物梅里埃在2024年1月发布的新闻稿《生物梅里埃收购LUMED以加强软体产品组合》中宣布，已完成约900万欧元的投资，收购了这家软体开发公司剩余的股份，并将其临床决策支援系统全面整合到其全球产品组合中。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球血液感染检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 产品类别（试剂/耗材、设备）
  • 样本类型（全血、血液培养）
  • 透过技术（PCR、质谱、原位杂合反应等）
  • 按最终用户（医院/诊断中心、客製化检测服务供应商、学术/研究机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美血液感染检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲血液感染检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区血液感染检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲血液感染检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲血液感染检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球血液感染检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• bioMerieux SA
• Becton, Dickinson and Company
• Cepheid
• Seegene Inc
• T2 Biosystems, Inc
• F. Hoffmann-La Roche Ltd
• Siemens Healthcare Private Limited
• Luminex Corporation
• Bruker Corporation
• Accelerate Diagnostics, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Bloodstream Infection Testing Market is projected to expand from USD 850.50 Million in 2025 to USD 1140.41 Million by 2031, achieving a compound annual growth rate of 5.01%. This sector encompasses diagnostic instruments, consumables, and software utilized for the detection and identification of pathogens, such as bacteria and fungi, in blood samples. Growth is largely propelled by the rising incidence of sepsis and the critical necessity of managing antimicrobial resistance through accurate etiological diagnoses. Emphasizing this urgent need, the European Centre for Disease Prevention and Control reported in 2024 that the estimated total incidence of third-generation cephalosporin-resistant Escherichia coli bloodstream infections in the EU was 11.03 per 100,000 population, demonstrating the essential role of precise testing in directing therapeutic actions and enhancing patient recovery.

However, the market faces significant hurdles due to the high costs and technical complexities linked to automated molecular diagnostic systems. Numerous healthcare facilities, especially within developing nations, contend with budgetary limitations that preclude the acquisition of these rapid testing solutions, necessitating a continued reliance on slower, traditional culture-based methods. These financial barriers impede timely treatment decisions and restrict the global reach of advanced diagnostic technologies, thereby limiting their availability in regions where they are frequently most essential.

Market Driver

The escalating challenge of antimicrobial resistance serves as a primary driver for the Global Bloodstream Infection Testing Market. As pathogens develop defenses against standard treatments, healthcare providers are increasingly seeking diagnostic tools capable of both identifying causative agents and determining antibiotic susceptibility profiles. This rise in resistant strains mandates the use of advanced testing platforms to facilitate precise therapeutic interventions and prevent fatalities. For instance, the UK Health Security Agency's November 2024 'English surveillance of antibiotic prescribing and utilisation report' highlighted that bacteraemia cases attributed to antibiotic resistance in England rose by 9.3% year-over-year, totaling 20,484 cases in 2024, underscoring the demand for diagnostics that manage resistant infections effectively.

Concurrently, breakthroughs in rapid molecular diagnostic technologies are transforming the speed and precision of pathogen detection. While traditional culture methods can take days to produce results-a potentially fatal delay in sepsis management-modern platforms offer actionable data within hours to optimize clinical workflows. A study published in the 'Journal of Clinical Microbiology' in March 2024 involving T2 Biosystems demonstrated that the T2Resistance Panel achieved 94.7% sensitivity and provided results in only 4.4 hours, compared to more than 58 hours for standard blood cultures. This functional advantage is attracting significant investment; according to Respiratory Therapy, diagnostic firm Cytovale secured $100 million in Series D funding in 2024 to accelerate the deployment of its rapid sepsis testing technology across hospital systems.

Market Challenge

The substantial expense and technical intricacy associated with automated molecular diagnostic platforms present a major obstacle to the expansion of the Global Bloodstream Infection Testing Market. High acquisition prices combined with the need for specialized operational skills make these systems unattainable for many healthcare facilities, particularly in areas facing strict financial constraints. These economic and operational barriers compel laboratories to rely on slower, traditional culture methods, which delays critical treatment decisions and hinders the widespread adoption of modern testing technologies.

This financial strain is further highlighted by the minimal budget allocation for diagnostic solutions, which restricts the purchasing capacity of medical institutions. According to MedTech Europe, expenditure on in vitro diagnostics accounted for merely 0.6% of total healthcare spending in Europe in 2024. Such restricted investment underscores the challenges facilities face in funding high-cost automated platforms. Consequently, market growth is directly impeded as the advanced capabilities of these instruments remain inaccessible to a significant portion of the global healthcare sector due to enduring funding limitations.

Market Trends

The integration of Artificial Intelligence and Machine Learning algorithms is fundamentally transforming clinical workflows by shifting focus from simple pathogen detection to predictive risk stratification. Unlike conventional diagnostics that identify organisms after an infection is established, AI models analyze host-immune responses and vital sign fluctuations to predict sepsis onset hours in advance, allowing clinicians to intervene before irreversible organ damage occurs. Validating this innovation, Prenosis announced in an April 2024 press release titled 'Prenosis Announces FDA De Novo Marketing Authorization of the Sepsis ImmunoScore' that it received the first-ever marketing authorization for an AI tool assessing 22 distinct parameters to evaluate patient sepsis risk.

Strategic industry consolidations and collaborative partnerships are further driving market evolution as major diagnostic players aim to provide comprehensive, end-to-end sepsis management solutions. Leading companies are acquiring niche software and technology firms to bridge the gap between diagnostic hardware and antimicrobial stewardship, converting standalone instruments into integrated data ecosystems that enhance hospital-wide decision-making. Illustrating this approach, bioMerieux announced in a January 2024 press release titled 'bioMerieux acquires LUMED to reinforce its software portfolio' that it completed an investment of nearly 9 million euros to acquire the remaining capital of the software developer, thereby fully integrating its clinical decision support systems into their global offering.

Key Market Players

• bioMerieux SA
• Becton, Dickinson and Company
• Cepheid
• Seegene Inc
• T2 Biosystems, Inc
• F. Hoffmann-La Roche Ltd
• Siemens Healthcare Private Limited
• Luminex Corporation
• Bruker Corporation
• Accelerate Diagnostics, Inc

Report Scope

In this report, the Global Bloodstream Infection Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bloodstream Infection Testing Market, By Product

• Reagents & Consumables
• Instruments

Bloodstream Infection Testing Market, By Sample Type

• Whole Blood
• Blood Culture

Bloodstream Infection Testing Market, By Technology

• PCR
• Mass Spectroscopy
• In Situ Hybridization
• Others

Bloodstream Infection Testing Market, By End User

• Hospitals & Diagnostic Centers
• Custom Laboratory Service Providers
• Academic & Research Institutes
• Others

Bloodstream Infection Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bloodstream Infection Testing Market.

Available Customizations:

Global Bloodstream Infection Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bloodstream Infection Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Reagents & Consumables, Instruments)
  • 5.2.2. By Sample Type (Whole Blood, Blood Culture)
  • 5.2.3. By Technology (PCR, Mass Spectroscopy, In Situ Hybridization, Others)
  • 5.2.4. By End User (Hospitals & Diagnostic Centers, Custom Laboratory Service Providers, Academic & Research Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Bloodstream Infection Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Sample Type
  • 6.2.3. By Technology
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bloodstream Infection Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Sample Type
      • 6.3.1.2.3. By Technology
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Bloodstream Infection Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Sample Type
      • 6.3.2.2.3. By Technology
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Bloodstream Infection Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Sample Type
      • 6.3.3.2.3. By Technology
      • 6.3.3.2.4. By End User

7. Europe Bloodstream Infection Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Sample Type
  • 7.2.3. By Technology
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bloodstream Infection Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Sample Type
      • 7.3.1.2.3. By Technology
      • 7.3.1.2.4. By End User
  • 7.3.2. France Bloodstream Infection Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Sample Type
      • 7.3.2.2.3. By Technology
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Bloodstream Infection Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Sample Type
      • 7.3.3.2.3. By Technology
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Bloodstream Infection Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Sample Type
      • 7.3.4.2.3. By Technology
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Bloodstream Infection Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Sample Type
      • 7.3.5.2.3. By Technology
      • 7.3.5.2.4. By End User

8. Asia Pacific Bloodstream Infection Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Sample Type
  • 8.2.3. By Technology
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Bloodstream Infection Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Sample Type
      • 8.3.1.2.3. By Technology
      • 8.3.1.2.4. By End User
  • 8.3.2. India Bloodstream Infection Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Sample Type
      • 8.3.2.2.3. By Technology
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Bloodstream Infection Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Sample Type
      • 8.3.3.2.3. By Technology
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Bloodstream Infection Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Sample Type
      • 8.3.4.2.3. By Technology
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Bloodstream Infection Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Sample Type
      • 8.3.5.2.3. By Technology
      • 8.3.5.2.4. By End User

9. Middle East & Africa Bloodstream Infection Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Sample Type
  • 9.2.3. By Technology
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Bloodstream Infection Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Sample Type
      • 9.3.1.2.3. By Technology
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Bloodstream Infection Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Sample Type
      • 9.3.2.2.3. By Technology
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Bloodstream Infection Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Sample Type
      • 9.3.3.2.3. By Technology
      • 9.3.3.2.4. By End User

10. South America Bloodstream Infection Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Sample Type
  • 10.2.3. By Technology
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Bloodstream Infection Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Sample Type
      • 10.3.1.2.3. By Technology
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Bloodstream Infection Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Sample Type
      • 10.3.2.2.3. By Technology
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Bloodstream Infection Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Sample Type
      • 10.3.3.2.3. By Technology
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Bloodstream Infection Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. bioMerieux SA
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Becton, Dickinson and Company
• 15.3. Cepheid
• 15.4. Seegene Inc
• 15.5. T2 Biosystems, Inc
• 15.6. F. Hoffmann-La Roche Ltd
• 15.7. Siemens Healthcare Private Limited
• 15.8. Luminex Corporation
• 15.9. Bruker Corporation
• 15.10. Accelerate Diagnostics, Inc

16. Strategic Recommendations

17. About Us & Disclaimer